{
  "completed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9
  ],
  "results": [
    {
      "example_idx": 0,
      "dataset_id": "1511",
      "question": "What is a lockdown?",
      "ground_truth_answer": "A lockdown is the implementation of strict restrictions and measures to limit people's movement and activities in order to control the spread of infections, such as the one mentioned in the given context.",
      "generated_response": "<think>\nOkay, the user is asking, \"What is a lockdown?\" and the context provided seems to be about estimating infections and the impact of non-lockdown measures. Wait, the titles and passages are a bit confusing. Let me look again.\n\nThe context has four entries. The first three are titled \"Estimating the number of infections and the impact of non-\" with the passage \"Lockdown\" each time. The fourth title is the same but the passage is \"banned Implemented with lockdown.57 24/3/2020\". Hmm, maybe there's a formatting issue here. It looks like the titles might be cut off. The first part of the title is \"Estimating the number of infections and the impact of non-\" and then the passage is \"Lockdown\". So perhaps the full title is \"Estimating the number of infections and the impact of non-lockdown measures\"? That would make sense. The fourth entry's passage mentions \"banned Implemented with lockdown.57 24/3/2020\" which could be a date or a reference.\n\nGiven that, the context is likely discussing studies or reports on how lockdowns affect the spread of infections, compared to non-lockdown approaches. The user's question is about defining a lockdown. Since the context is about the impact of lockdowns, the answer should define a lockdown in the context of public health measures, probably related to containing infectious diseases like COVID-19. A lockdown typically involves strict restrictions on movement, closure of non-essential businesses, and social distancing measures to prevent the spread of disease. The answer should be concise, based on the context provided, which seems to focus on the role of lockdowns in reducing infections.\n</think>\n\nA lockdown is a public health measure implemented to restrict movement and gatherings of people in order to slow the spread of infectious diseases, such as during the COVID-19 pandemic. It typically involves closing non-essential businesses, schools, and public spaces, limiting travel, and enforcing strict social distancing rules. The context provided suggests that lockdowns are analyzed for their impact on reducing infections compared to non-lockdown strategies.",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.2,
      "gt_utilization": 0.2,
      "gt_completeness": 1.0,
      "gt_adherence": 0.0,
      "binary_pred": 1,
      "binary_gt": 0,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 1,
      "dataset_id": "1085",
      "question": "What complications are associated with CHIKV?",
      "ground_truth_answer": "Complications associated with CHIKV include respiratory failure, cardiovascular decompensation, meningoencephalitis, severe acute hepatitis, severe cutaneous effects, other central nervous system problems, and kidney failure.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking about the complications associated with CHIKV, which I know stands for Chikungunya virus. I need to look through the provided context to find all the mentioned complications.\n\nFirst, looking at the first passage, it lists several complications from most common to least. The main ones are respiratory failure, cardiovascular decompensation, meningoencephalitis, severe acute hepatitis, severe cutaneous effects, other central nervous system problems, and kidney failure. That's a good list to start with.\n\nThen, in the third passage about the La Reunion Island outbreak, there's mention of neonates developing mengoencephalitis (probably a typo for meningoencephalitis). Also, six neonates had this, and there were fetal deaths. The fourth passage by Gerardin et al. talks about neonatal infections leading to encephalitis through vertical transmission. So encephalitis, especially in newborns, is another complication.\n\nI should make sure to include all these complications. The answer should list them, noting that some are more common than others. Also, the neonatal cases add specific complications related to mother-to-child transmission. Let me check if there are any other complications mentioned. The first passage also mentions \"other central nervous system problems,\" so maybe that's broader than just encephalitis. Also, fetal deaths are a complication from maternal infection.\n\nPutting it all together: the main complications are respiratory failure, cardiovascular issues, meningoencephalitis, hepatitis, skin issues, CNS problems, kidney failure, and in neonates, encephalitis and fetal deaths. Need to present them clearly, perhaps grouping the common ones first and then the others.\n</think>\n\nThe complications associated with Chikungunya virus (CHIKV) include:  \n1. **Respiratory failure**  \n2. **Cardiovascular decompensation**  \n3. **Meningoencephalitis** (including neonatal cases due to vertical transmission)  \n4. **Severe acute hepatitis**  \n5. **Severe cutaneous effects**  \n6. **Other central nervous system (CNS) problems**  \n7. **Kidney failure**  \n\nAdditional complications from vertical transmission (mother to child) include **neonatal encephalitis** and **fetal deaths**, as observed during outbreaks like the 2005\u20132006",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.2,
      "gt_utilization": 0.2,
      "gt_completeness": 1.0,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 2,
      "dataset_id": "1696",
      "question": "How do the S1 subunits compare with that of SARS-likeCOV and human SARS-COV?",
      "ground_truth_answer": "The S1 subunit of 2019-nCoV shares around 70% identity with those of two bat SARS-like CoVs and human SARS-CoV.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking how the S1 subunits of the 2019-nCoV (which is SARS-CoV-2) compare to those of SARS-like coronaviruses (SARSr-CoVs) and human SARS-CoV. \n\nFirst, I need to look through the provided context passages. The first passage mentions that the S2 subunit is highly conserved with 99% identity, but the question is about the S1 subunit. The second passage starts with \"Though the S1 subunit of 2019-nCoV shares around 70% identity to that of the two bat SARS-like CoVs and human SARS-CoV...\" So that's a key point. The S1 subunit has about 70% identity with those viruses.\n\nThen, the third passage says that the external subdomain of the RBD (receptor-binding domain) in the S1 subunit shares only 40% amino acid identity with other SARS-related coronaviruses. The RBD is part of the S1 subunit, so this indicates that while there's some similarity in the overall S1 subunit (70%), the specific part that interacts with the host receptor (the external subdomain) is more divergent (40%).\n\nSo putting this together, the S1 subunit of 2019-nCoV has about 70% identity with SARS-like and human SARS-CoV, but the receptor-binding domain's external part is only 40% identical. This suggests that while there's some conservation, the part responsible for receptor interaction is different, which might explain differences in host range or pathogenicity. The answer should reflect both the overall 70% identity and the lower 40% in the RBD's external subdomain.\n</think>\n\nThe S1 subunit of 2019-nCoV (SARS-CoV-2) shares **approximately 70% amino acid identity** with the S1 subunits of bat SARS-like coronaviruses (SARSr-CoVs) and human SARS-CoV. However, the **receptor-binding domain (RBD)** within the S1 subunit exhibits lower conservation: its **external subdomain**, responsible for direct interaction with the host receptor, shows only **40% amino acid",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.12,
      "gt_utilization": 0.04,
      "gt_completeness": 0.3333333333333333,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 3,
      "dataset_id": "669",
      "question": "What is Bacillus subtilis?",
      "ground_truth_answer": "Bacillus subtilis is a species of bacteria that has been shown to be effective in the prevention and/or treatment of intestinal diseases such as diarrhea, colitis, irritable bowel syndrome, irritable bowel disease, and colorectal cancer. It is also a part of the normal intestinal microbiome and has been found in the healthy human gastrointestinal tract. Bacillus subtilis produces surfactins, fengycins, and iturins, which have antimicrobial and antiviral properties.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking, \"What is Bacillus subtilis?\" I need to base my answer on the provided context.\n\nFirst, I'll look through the passages. The first passage mentions that B. subtilis is a probiotic used to treat intestinal diseases like colitis. It helps restore gut microflora by increasing beneficial bacteria and decreasing harmful ones. It also maintains gut barrier integrity and reduces inflammation. The second passage lists B. subtilis as part of commercial probiotics like Biosubtyl and others. The third passage talks about Bacillus species being part of the gut microbiome, even though they were once considered transient.\n\nPutting this together, Bacillus subtilis is a type of Bacillus that's used as a probiotic. It's beneficial for the gut, helps with various intestinal issues, and is found in some fermented foods and probiotic products. I should mention its role in restoring gut flora balance, reducing inflammation, and its presence in commercial products. Also, note that it's part of the gut microbiome despite being a soil organism. Need to make sure the answer is concise and covers all key points from the context without adding external info.\n</think>\n\nBacillus subtilis is a species of the Bacillus genus, recognized as a probiotic with significant benefits for intestinal health. It is used in the prevention and treatment of intestinal diseases such as colitis, diarrhea, and irritable bowel syndrome. As a probiotic, **B. subtilis** helps restore gut microbiota balance by increasing beneficial bacteria (e.g., *Bifidobacterium*, *Lactobacillus*, *Butyricicoccus*) and reducing harmful species (e.g., *Acinetobacter*, *Clostridium*). It also strengthens gut barrier integrity, lowers endotoxin levels, and reduces inflammation. Historically considered transient in the gut due to its soil origin, recent studies confirm its presence in the gastrointestinal tract. It is included in commercial probiotic products like **Biosubtyl** and **Enterogermina** and is applied in fermented foods for its health-promoting properties.",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.4090909090909091,
      "gt_utilization": 0.18181818181818182,
      "gt_completeness": 0.3333333333333333,
      "gt_adherence": 0.0,
      "binary_pred": 1,
      "binary_gt": 0,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 4,
      "dataset_id": "1564",
      "question": "How many reported viral pneumonia?",
      "ground_truth_answer": "The passage does not provide a specific number of reported viral pneumonia cases overall. However, it mentions 2744 confirmed cases of pneumonia with 2019-nCoV infection in China, and it also mentions 77 fatal cases of pandemic H1N1v 2009 infection.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking \"How many reported viral pneumonia?\" based on the provided context. Let me look through each of the given passages to find relevant information.\n\nFirst, the first passage is about the 2019-nCoV (now known as COVID-19) in China. It mentions 2744 confirmed cases of pneumonia with 2019-nCoV infection. That's a specific number related to that virus. The other passages are about influenza, specifically the 2009 H1N1 pandemic and seasonal influenza. They discuss bacterial co-infections and attack rates but don't provide specific numbers of reported viral pneumonia cases beyond percentages and examples like the La Gloria outbreak where they mention attack rates (29% and 61%), but not actual numbers.\n\nThe question is asking for the number of reported viral pneumonia cases. The only passage that gives a specific number is the first one about 2019-nCoV, which states 2744 confirmed cases. The other passages don't mention specific numbers of cases, just percentages and some examples of attack rates. The user might be confused if they think there are other numbers, but based on the provided context, only the 2744 from the first passage is a direct count. The rest are about influenza in general without specific case numbers. So the answer should be 2744.\n</think>\n\nThe context provided includes specific data on 2019-nCoV (COVID-19) cases, with **2,744 confirmed cases of pneumonia** reported as of 24:00 on 26 January 2020. The other passages discuss influenza-related pneumonia (e.g., H1N1) but focus on attack rates, co-infection prevalence, or demographic trends without specifying exact numbers of reported viral pneumonia cases. \n\n**Answer:** 2,744 cases of 2019-nCoV-infected pneumonia were reported.",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.125,
      "gt_utilization": 0.125,
      "gt_completeness": 1.0,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 5,
      "dataset_id": "1247",
      "question": "How has most of the analysis of MERS-CoV genetics  been performed?",
      "ground_truth_answer": "Most of the analysis of MERS-CoV genetics has been performed using high throughput or \"deep\" sequencing methods for complete genome deduction.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking how most of the analysis of MERS-CoV genetics has been performed. I need to look at the provided context to find the answer.\n\nLooking at the first passage under the title \"MERS coronavirus: diagnostics, epidemiology and transmission,\" the first sentence says, \"Most of the analysis of MERS-CoV genetics has been performed using high throughput or 'deep' sequencing methods for complete genome deduction.\" That seems like the direct answer. The passage also mentions that MERS-CoV was the first to have such widespread use of deep sequencing for studying an emerging viral outbreak. \n\nI should check the other passages to make sure there's no conflicting information. The second passage talks about genome analyses showing single nucleotide differences and specific regions of the genome, but it doesn't mention the method used. The third passage discusses vigilance and the importance of sequencing and analysis but again doesn't specify the method. \n\nSo the key information is in the first passage. The answer should be that high throughput or deep sequencing methods were used for complete genome deduction. The user might also want to know that this was a significant approach for studying MERS-CoV, as it allowed comprehensive genomic analysis. I need to present this clearly and concisely, making sure to reference the context provided.\n</think>\n\nMost of the analysis of MERS-CoV genetics has been performed using **high throughput or \"deep\" sequencing methods** for complete genome deduction. This approach enabled comprehensive genomic studies of MERS-CoV, marking it as the first instance of such widespread use of deep sequencing to investigate an emerging viral outbreak with global reach. The technique allows for detailed genomic coverage and repetitive measurement of nucleotide positions in a single experiment.",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.2857142857142857,
      "gt_utilization": 0.047619047619047616,
      "gt_completeness": 0.16666666666666666,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 6,
      "dataset_id": "1129",
      "question": "How were  the spread of GFP-expressing virus-infected cells tracked?",
      "ground_truth_answer": "The spread of GFP-expressing virus-infected cells was tracked using immunofluorescence microscopy, whole-organ imaging with IVIS, flow cytometry, and inverted fluorescence microscopy.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking how the spread of GFP-expressing virus-infected cells was tracked. I need to look at the provided contexts to find the relevant information.\n\nFirst, looking at the first context: They mention using a split-GFP-tagged viral protein. They transduced cells with MLV particles, concentrated them, and then used puromycin to select for GFP-expressing cells. They also used immunofluorescence microscopy with a GFP antibody to monitor expression during passaging. But this seems more about generating stable cell lines rather than tracking spread.\n\nThe second context talks about bat cell lines and zoonotic emergence. They used an inverted fluorescence microscope to monitor plates after applying an overlay. Once they saw GFP expression, they imaged a subset of each well using a CellInsight CX5 platform with a 4X objective. They kept microscope settings standard, fixed exposure time, and imaged one color channel. This part mentions tracking over time by periodic imaging, which might be how they monitored the spread.\n\nThird context discusses in vivo visualization using multi-photon microscopy. They mention using fluorescent proteins like EGFP and mCherry in mouse lines, allowing long-term tracking without bleaching. Also, the signal-to-noise ratio helps visualize small structures. This is about in vivo tracking, but the question might be about in vitro methods.\n\nThe question is about tracking the spread of GFP-expressing virus-infected cells. The second context's method seems most relevant. They used periodic imaging with a high-content screening platform after initial detection of GFP. The first context's immunofluorescence microscopy is for monitoring during passaging but not tracking spread over time. The third context's multi-photon is for in vivo, which might not be the answer here.\n\nSo the answer would combine elements from the second context: using fluorescence microscopy (inverted microscope and CellInsight platform), periodic imaging, fixed settings, and specific imaging parameters. They tracked by taking images over time, focusing on GFP expression areas. The first context's method is about generating cells, not tracking spread. The third is in vivo, which isn't the focus here. Therefore, the main method is periodic imaging with fluorescence microscopy using a high-content screening platform after detecting initial GFP expression.\n</think>\n\nThe spread of GFP-expressing virus-infected cells was tracked using **periodic fluorescence microscopy imaging**. Specifically, after detecting initial GFP expression via an",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.21052631578947367,
      "gt_utilization": 0.21052631578947367,
      "gt_completeness": 1.0,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 7,
      "dataset_id": "790",
      "question": "What can RNA sequencing be used to monitor?",
      "ground_truth_answer": "RNA sequencing can be used to monitor transcripts that may not be in the existing genomic annotation, allowing the search for novel transcripts, and even identification of SNPs and other variants, as well as for transcriptome profiling in cancers such as breast cancer, gastrointestinal tumors, and prostate cancer.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking, \"What can RNA sequencing be used to monitor?\" and they provided three context passages. I need to go through each one and see what information is relevant.\n\nFirst, looking at the first passage titled \"Personal genomes...\" It mentions that RNA-Seq provides information on transcripts not in existing genomic annotations, allowing the search for novel transcripts, SNPs, and other variants. It also lists cancers like breast, gastrointestinal, and prostate. So RNA sequencing can monitor novel transcripts, SNPs, variants, and is used in cancer studies.\n\nThe second passage is about identifying microorganisms using DNA microarrays. It talks about pathogen identification and the need for large databases. But the question is about RNA sequencing. Wait, the second passage mentions DNA microarrays and PCR, but not RNA-Seq directly. Maybe not directly relevant unless there's a connection. The third passage is about single-cell RNA analysis, mentioning RNA sequencing as an alternative to qRT-PCR and microarrays. It's about single-cell level analysis.\n\nSo combining all the info: RNA-Seq can monitor transcriptomes, find novel transcripts, SNPs, variants, used in cancer profiling, and in single-cell analysis. The answer should include these points. The user wants the answer based on the provided contexts. Need to make sure not to include external knowledge. Let me check again each passage.\n\nFirst passage: RNA-Seq provides transcript info, novel transcripts, SNPs, variants, and used in cancers. Second passage is about DNA microarrays for pathogens, but maybe not RNA-Seq. Third passage is about single-cell RNA analysis, so RNA-Seq is used there. So the answer should include monitoring transcriptomes, novel transcripts, SNPs, variants, cancer types, and single-cell transcriptomics. Also, maybe pathogen identification? Wait, the second passage is about DNA microarrays for pathogens, but the question is about RNA sequencing. Unless there's a mention of RNA-Seq in that context. The second passage doesn't mention RNA-Seq, so probably not. So stick to the first and third passages. \n\nSo the answer would be RNA sequencing can monitor transcriptomes, identify novel transcripts, SNPs, other variants, used in cancer profiling (breast, gastrointestinal, prostate), and single-cell transcriptomic analysis. Also, the first passage mentions reproducibility, but that's more about the method's reliability, not what it monitors. The",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.38095238095238093,
      "gt_utilization": 0.09523809523809523,
      "gt_completeness": 0.25,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 8,
      "dataset_id": "480",
      "question": "In what direction does the Vesicular stomatitis virus spread through the nervous system?",
      "ground_truth_answer": "The Vesicular stomatitis virus spreads in a retrograde direction through the nervous system.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking about the direction in which the Vesicular stomatitis virus (VSV) spreads through the nervous system based on the provided context.\n\nFirst, I need to look at the context given. The title mentions that the virus with the rabies virus glycoprotein directs retrograde transsynaptic transport. The passage talks about rVSV (recombinant VSV) spreading in a retrograde direction from the injection site. The study uses a unidirectional circuit, specifically the primary motor cortex to CP connection, where neurons project from the cortex to CP but not vice versa. When they injected rVSV into M1 (primary motor cortex), they didn't label neurons in the CP if the virus only spreads retrogradely. At 2 days post-injection (dpi), the labeling was restricted, and by 5 dpi, it stayed within corticostriatal circuits. Also, the efficiency decreases after crossing one or two connections. \n\nSo, the key points here are \"retrograde direction\" and the use of a unidirectional circuit to confirm that the spread is only retrograde. The fact that when injected into M1, CP wasn't labeled supports that the virus can't spread anterogradely. The mention of retrograde transsynaptic transport in the title and the experimental setup all point to the virus moving in the retrograde direction. \n\nI should make sure there's no mention of anterograde spread. The passage says that if the virus could only spread retrograde, then CP shouldn't be labeled, which was observed. Also, the efficiency decreasing after a couple of connections suggests it's moving step by step in one direction. \n\nTherefore, the answer should be that the virus spreads in the retrograde direction.\n</think>\n\nThe Vesicular stomatitis virus (VSV) spreads in a **retrograde direction** through the nervous system. The context explicitly states that the recombinant VSV (rVSV) spreads retrogradely from the injection site, as demonstrated by experiments using a unidirectional circuit (primary motor cortex to CP connection). Injections into the primary motor cortex (M1) did not label neurons in the CP, confirming retrograde transsynaptic transport. Additionally, the virus's spread became less efficient after crossing one or two synapses, further supporting its retrograde movement.",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.2,
      "gt_utilization": 0.2,
      "gt_completeness": 1.0,
      "gt_adherence": 1.0,
      "binary_pred": 1,
      "binary_gt": 1,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    },
    {
      "example_idx": 9,
      "dataset_id": "1585",
      "question": "How do these exact processes ultimately restrict viral infectivity?",
      "ground_truth_answer": "These processes ultimately restrict viral infectivity by triggering a legion of cellular defense and antiviral systems, inducing inflammatory factors and activating innate and adaptive immunity. Additionally, these mechanisms include the activation of direct antiviral activity against the replicative stages of viruses, targeting common pathways or structures that are essential for viral replication. This evolutionary arms race between countermeasures and species-specific factors ultimately prevent effective viral envelope clustering, decrease fluidity and imposes rigidity, and induce an outward membrane curvature that opposes the forces exerted by viral fusion machinery, ultimately inhibiting the ins and outs of HIV replication and restricting viral infectivity.",
      "generated_response": "<think>\nOkay, let's tackle this question. The user is asking how these exact processes ultimately restrict viral infectivity. The context provided includes three passages about antiviral mechanisms, specifically mentioning HIV and flaviviruses like TBFV and TBEV.\n\nFirst, I need to parse the key points from each passage. The first passage talks about cell-intrinsic antiretroviral restrictions related to HIV replication at the plasma membrane. It mentions that mammalian hosts have evolved mechanisms to inhibit viral entry and exit, which are common to enveloped viruses. These mechanisms are regulated by type 1 interferons and pattern recognition responses, linking them to the broader immune response.\n\nThe second passage discusses viral persistence in flaviviruses. It notes that when cells are infected, defense systems like type I and III interferons, mitochondrial signaling, and inflammatory factors (like interleukins) are activated. An example given is TRIM79a restricting TBEV by degrading NS5. It also mentions that these factors could lead to cell death via apoptosis.\n\nThe third passage is a continuation of the first one, mentioning that some interferon-stimulated genes (ISGs) are activated by pattern recognition responses and have direct antiviral activity against various viruses. These restriction factors target common pathways in viral replication.\n\nThe question is about how these processes restrict viral infectivity. The answer should tie together the mechanisms described: interferons (type I and III), pattern recognition responses, ISGs, restriction factors like TRIM79a, and their effects on viral replication stages (entry, exit, replication). Also, the activation of apoptosis as a result of these defenses might be a point to mention since it limits viral spread by killing infected cells.\n\nI need to ensure that the answer connects the activation of these antiviral systems through interferons and pattern recognition, the direct action of restriction factors on viral components (like degrading viral proteins), and the systemic immune response. Also, the idea that viruses have evolved countermeasures but the host's mechanisms still effectively restrict infectivity by targeting essential steps in the viral life cycle.\n\nI should avoid introducing new information not in the context. Make sure to mention the specific examples given, like TRIM79a and NS5 degradation. Also, note that these mechanisms are regulated by interferons and pattern recognition, which link to both innate and adaptive immunity. The answer should explain that by targeting entry, replication, and exit, and inducing cell",
      "retrieved_chunks": [],
      "computed_relevance": 0.0,
      "computed_utilization": 0.0,
      "computed_completeness": 0.0,
      "computed_adherence": 1.0,
      "gt_relevance": 0.38095238095238093,
      "gt_utilization": 0.38095238095238093,
      "gt_completeness": 1.0,
      "gt_adherence": 0.0,
      "binary_pred": 1,
      "binary_gt": 0,
      "is_valid": true,
      "is_rate_limited": false,
      "is_skipped": false,
      "error": ""
    }
  ],
  "skipped_samples": []
}